NBY vs. ME, UBX, ALVR, NEUP, IMNN, TXMD, ABP, NXTC, IBIO, and NERV
Should you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include 23andMe (ME), UNITY Biotechnology (UBX), AlloVir (ALVR), Neuphoria Therapeutics (NEUP), Imunon (IMNN), TherapeuticsMD (TXMD), Abpro (ABP), NextCure (NXTC), iBio (IBIO), and Minerva Neurosciences (NERV). These companies are all part of the "pharmaceutical products" industry.
NovaBay Pharmaceuticals vs. Its Competitors
NovaBay Pharmaceuticals (NYSE:NBY) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.
In the previous week, 23andMe had 11 more articles in the media than NovaBay Pharmaceuticals. MarketBeat recorded 12 mentions for 23andMe and 1 mentions for NovaBay Pharmaceuticals. 23andMe's average media sentiment score of 0.51 beat NovaBay Pharmaceuticals' score of 0.00 indicating that 23andMe is being referred to more favorably in the news media.
23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. Comparatively, 36.1% of 23andMe shares are held by institutional investors. 0.1% of NovaBay Pharmaceuticals shares are held by company insiders. Comparatively, 26.3% of 23andMe shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
NovaBay Pharmaceuticals has a net margin of -102.72% compared to 23andMe's net margin of -183.39%. 23andMe's return on equity of -170.07% beat NovaBay Pharmaceuticals' return on equity.
NovaBay Pharmaceuticals has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
NovaBay Pharmaceuticals currently has a consensus price target of $0.85, suggesting a potential upside of 35.14%. Given NovaBay Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe NovaBay Pharmaceuticals is more favorable than 23andMe.
NovaBay Pharmaceuticals has higher earnings, but lower revenue than 23andMe. 23andMe is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
23andMe beats NovaBay Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get NovaBay Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NovaBay Pharmaceuticals Competitors List
Related Companies and Tools
This page (NYSE:NBY) was last updated on 7/4/2025 by MarketBeat.com Staff
